ACT 16120/2024

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details: Status
—
Action
Infringement
Category
Main Infringement Action
Parties: Claimants
Sanofi SA
Sanofi Winthrop Industrie
Sanofi-Aventis GmbH
Sanofi Belgium
Sanofi-Aventis Deutschland GmbH
Sanofi S.r.l.
Sanofi B.V.
Sanofi - Produtos Farmaceuticos Lda
Sanofi AB
Sanofi A/S
Reps: Frédéric Chevallier (McDermott Will & Schulte)
Respondents
Zentiva Pharma GmbH
Zentiva France
Zentiva, k.s.
STADAPHARM GmbH
STADA Arzneimittel AG
STADA Nordic ApS
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Dr Reddy's Srl
Accord Healthcare S.L.U.
Accord Healthcare B.V.
Accord Healthcare GmbH (DE)
Accord Healthcare Italia Srl
Reps: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Division: Munich LD
Judges: Matthias Zigann · Presiding judge and judge-rapporteur
Technology: Pharmaceuticals · Oncology · Pharmaceutical & Medical
Language: —
First decided: Sep 15, 2025

Decisions

2025-09-15
Infringement Action
Munich Local Division order (judge-rapporteur Zigann) following the second interim conference in consolidated infringement proceedings by Sanofi entities against Zentiva, STADA, Dr. Reddy's and Accord Healthcare groups concerning EP 2 493 466 (insulin glargine). The order confirms the oral hearing dates (14-17 October 2025), orders all four counterclaims to be heard together with separate handling of each infringement action, and gives organisational directions for the hearing.
Legal issues:Oral hearing scheduling (R. 105.5 RoP)Coordination of joint counterclaims for revocation with multiple infringement actionsInsulin glargine / pharmaceutical patent

Documents